Novartis Q3FY26 Results: Core operating income rises 10%, guidance raised
Novartis reported Q3 net sales of $14.52B, up 4% YoY, with core operating income rising 10% to $6.04B. The company raised full-year guidance for core operating income. Despite this, reported operating income fell 61% due to a $1.9B impairment charge. Key growth drivers included Kisqali and Kesimpta. Novartis also announced Gagan Sharma as President, Specialty Business for its Indian subsidiary, Evonile Pharma.
How this was made
The 30-second read
Why it matters
The guidance upgrade is a primary earnings event that can drive short‑term price appreciation.
Market read
First‑report earnings with guidance raise for a large‑cap pharma; high relevance for traders.
What to watch
The $1.9B impairment on the del‑desiran asset highlights execution risk in late‑stage trials.
Background
Novartis disclosed Q3 FY26 results, showing modest sales growth but strong core operating income and raised guidance.
Ticker impact
Novartis reported Q3 FY26 results with a 10% rise in core operating income and raised full-year guidance.
likely upside as investors price in stronger core operating income and upgraded guidance
The earnings beat on core income and the upward revision of guidance are fresh, material information for a large-cap pharma.
Market effects
May lift broader pharma sector as peers are re‑rated on stronger margins.
Positive for European and US markets where Novartis is a major component.
Adds to overall positive sentiment in global healthcare equities.
Counterpoint
The 61% drop in reported operating income could signal underlying pipeline risk that may weigh on the stock.
Key entities
- companyNovartis
Swiss‑based pharmaceutical giant listed on NYSE as NVS.
